COMP <GO>
ILMN vs DGX // EV/EBITDA & P/E VALUATION
Illumina Inc. (NASDAQ) VS. Quest Diagnostics Incorporated (NYSE) • 15-METRIC TALLY: ILMN 7
— DGX 6
▲ EV/EBITDA & P/E VALUATION LEADER: DGX
LAST: $235.99 (-18.64%) • MKT CAP: $43.80B
valuation
47.5x
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
valuation
16.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ILMN VS. DGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ILMN | DGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.10% | 33.20% | +32.90 | ILMN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | 10.30% | +7.90 | ILMN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 47.5x | 16.3x | +31.20 | DGX | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 4.88% | -2.75 | DGX | /fcf-yield <GO> |
| Operating Margin | 18.60% | 14.10% | +4.50 | ILMN | /operating-margins <GO> |
| Net Profit Margin | 19.60% | 9.00% | +10.60 | ILMN | /net-margins <GO> |
| Revenue Growth (YoY) | -0.70% | 11.80% | -12.50 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.27% | -1.27 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 4.01 | +5.51 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.1 | 69.4 | -12.30 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.01 | +0.15 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.9x | 26.1x | +21.80 | DGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $43.80B | $27.83B | $15.97B | ILMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ILMN REV | DGX REV | ILMN GROSS % | DGX GROSS % | ILMN FCF | DGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.34B | $11.04B | 66.1% | 33.2% | $931.0M | $1.36B |
| FY 2024 | $4.37B | $9.87B | 65.4% | 32.9% | $709.0M | $909.0M |
| FY 2023 | $4.50B | $9.25B | — | — | $275.3M | $855.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ILMN // BETA 1.16
DGX // BETA 1.01